Projecting the effectiveness of RotaTeq® against rotavirus-related hospitalisations in Brazil
Mem. Inst. Oswaldo Cruz
;
106(5): 541-545, Aug. 2011. tab
Article
in English
| LILACS
| ID: lil-597712
ABSTRACT
RotaTeq® (Merck & Company, Inc, Whitehouse Station, NJ, USA) is an oral pentavalent rotavirus vaccine (RV5) that has shown high and consistent efficacy in preventing rotavirus gastroenteritis (RGE) in randomised clinical trials previously conducted in industrialised countries with high medical care resources. To date, the efficacy and effectiveness data for RV5 are available in some Latin American countries, but not Brazil. In this analysis, we projected the effectiveness of RV5 in terms of the percentage reduction in RGE-related hospitalisations among children less than five years of age in four regions of Brazil, using a previously validated mathematical model. The model inputs included hospital-based rotavirus surveillance data from Goiânia, Porto Alegre, Salvador and São Paulo from 2005-2006, which provided the proportions of rotavirus attributable to serotypes G1, G2, G3, G4 and G9, and published rotavirus serotype-specific efficacy from the Rotavirus Efficacy and Safety Trial. The model projected an overall percentage reduction of 93 percent in RGE-related hospitalisations, with an estimated annual reduction in RGE-related hospitalisations between 42,991-77,383 in the four combined regions of Brazil. These results suggest that RV5 could substantially prevent RGE-related hospitalisations in Brazil.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Rotavirus Infections
/
Rotavirus Vaccines
/
Gastroenteritis
Type of study:
Controlled clinical trial
/
Evaluation studies
/
Risk factors
Limits:
Adolescent
/
Child
/
Child, preschool
/
Female
/
Humans
/
Infant
/
Male
Country/Region as subject:
South America
/
Brazil
Language:
English
Journal:
Mem. Inst. Oswaldo Cruz
Journal subject:
Tropical Medicine
/
Parasitology
Year:
2011
Type:
Article
Affiliation country:
Brazil
/
United States
Institution/Affiliation country:
Clinical Research and Development, Novartis Vaccines & Diagnostics/US
/
Global Medical Affairs, Merck & Company, Inc/US
/
Merck Research Laboratories, Merck & Company, Inc/US
/
Universidade de São Paulo/BR
Similar
MEDLINE
...
LILACS
LIS